A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Primary Generalized Tonic-Clonic Seizures

In brief

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Key facts

Study ID
NCT05667142
Run by
Xenon Pharmaceuticals Inc.
People needed
160
Starts
2023-02-14
Expected to finish
2027-06-01
Last updated by the study team
2026-07-08

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.